Korea Joongang Daily
Korea JoongAng Daily

Korean companies mark record turnout at 2025 BIO USA

Korean firms, including Samsung Biologics and Celltrion, showcased innovations at the 2025 BIO International Convention in Boston, amid geopolitical tensions and competition from China, as over 80 companies participated.

2025-06-17

Celltrion gets interchangeability approval for biosimilar of Humira in the U.S.

Celltrion, a major Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for its biosimilar drug for autoimmune disease treatment in the United States.

2025-04-14

Celltrion chairman, two affiliates to buy back $135 million in shares

Celltrion's chairman and affiliates plan to buy 200 billion won of the company's shares in an effort to raise their value.

2025-04-09

Celltrion to cancel $140M in treasury shares

Celltrion will cancel treasury shares worth 203.3 billion won ($140 million) to enhance shareholder value, the Korean drugmaker said on Friday.

2025-03-14

Celltrion asthma drug Omlyclo approved for U.S. release

Celltrion's biosimilar Omlyclo has received U.S. FDA approval for various allergic conditions.

2025-03-10

Celltrion's bone disease biosimilars get approval in U.S.

Celltrion, a major Korean biopharmaceutical firm, said Tuesday that its two new biosimilars for bone disease treatment, Stoboclo and Osenvelt, have obtained approval from the United States.

2025-03-04

Celltrion Q4 net skyrockets on biosimilar sales, merger with affiliate

Celltrion reported increased profits from biosimilars and a merger.

2025-02-25

Celltrion announces 100 billion won share buyback

Celltrion plans to buy back 100 billion won ($69 million) in stocks, purchasing 554,632 shares starting Thursday.

2025-02-19

Celltrion's Actemra biosimilar gets FDA approval

Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.

2025-01-31

Celltrion's autoimmune disease treatment available in 5 European countries

Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European Commission approval last August.

2025-01-23